 | Up a level |
Journal Article
Heist, R. S., Garon, E. B., Tan, D. S. W., Groen, H. J. M., Seto, T., Smit, E. F., Nwana, N., Fairchild, L., Balbin, A., Yan, M., Wang, I., Giovannini, M., Sankaran, B. and Wolf, J. (2020). Accurate Detection of METex14 Mutations in Non-Small Cell Lung Cancer (NSCLC) with Comprehensive Genomic Sequencing: Results from the GEOMETRY Mono-1 Study. J. Thorac. Oncol., 15 (2). S. S30 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
Tan, D. S., Kim, S-W., Sequist, L. V., Ponce Aix, S., Smit, E. F., Hida, T., Yang, J. C-H., Felip, E., Seto, T., Grohe, C., Wolf, J., Ko, J., Marriere, E., Belli, R., Giovannini, M. and Kim, D-W. (2018). Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC). Ann. Oncol., 29. S. 748 - 749. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Thunnissen, E., Lissenberg-Witte, B., I, van den Heuvel, M. M., Monkhorst, K., Skov, B. G., Sorensen, J. B., Mellemgaard, A., Dingemans, A. M. C., Speel, E. J. M., de Langen, A. J., Hashemi, S. M. S., Bahce, I, van der Drift, M. A., Looijen-Salamon, M. G., Gosney, J., Postmus, P. E., Samii, S. M. S., Duplaquet, F., Weynand, B., Durando, X., Penault-Llorca, F., Finn, S., Grady, A. O., Oz, B., Akyurek, N., Buettner, R., Wolf, J., Bubendorf, L., Duin, S., Marondel, I, Heukamp, L. C., Timens, W., Schuuring, E. M. D., Pauwels, P. and Smit, E. F. (2019). ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. Lung Cancer, 138. S. 13 - 19. CLARE: ELSEVIER IRELAND LTD. ISSN 1872-8332
Vansteenkiste, J. F., Smit, E. F., Groen, H. J. M., Garon, E. B., Heist, R. S., Hida, T., Nishio, M., Kokowski, K., Grohe, C., Reguart, N., Mansfield, A. S., Robeva, A., Ghebremariam, S., Waldron-Lynch, M., Akimov, M., Nwana, N., Giovannini, M. and Wolf, J. (2020). Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study. Ann. Oncol., 31. S. S830 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Wolf, J., Groen, H. J. M., Akerley, W., Souquet, P. -J., Laack, E., Han, J. -Y., Smit, E. F., Mansfield, A. S., Garon, E. B., Tan, D. S. W., Heist, R. S., Waldron-Lynch, M., Le Mouhaer, S., Nwana, N., Giovannini, M. and Orlov, S. (2020). Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small- cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study. Oncol. Res. Treat., 43 (SUPPL 4). S. 143 - 144. BASEL: KARGER. ISSN 2296-5262
Wolf, J., Hochmair, M., Kattan, J. G., Ang, M. -K., Garon, E. B., Groen, H. J. M., Heist, R., Ohashi, K., Felip, E., Reguart, N., Garcia Campelo, R., Soo, R., Paz-Ares, L., de Marinis, F., Smit, E. F., Giovannini, M., Squires, M., Cui, X., Zhang, Y. and Tan, D. (2015). A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease. Ann. Oncol., 26. S. 146 - 147. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Wolf, J., Overbeck, T., Han, J. -Y., Hochmair, M., De Marinis, F., Ohashi, K., Smit, E. F., Power, D., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Waldron-Lynch, M., Le Mouhaer, S., Nwana, N., Giovannini, M. and Heist, R. S. (2020). Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. Oncol. Res. Treat., 43 (SUPPL 4). S. 150 - 152. BASEL: KARGER. ISSN 2296-5262
Wolf, J., Seto, T., Han, J-Y., Reguart, N., Garon, E. B., Groen, H. J. M., Tan, D. S., Hida, T., de Jonge, M. J. A., Orlov, S. V., Smit, E. F., Souquet, P-J., Vansteenkiste, J. F., Giovannini, M., Le Mouhaer, S., Robeva, A., Waldron-Lynch, M. and Heist, R. S. (2018). Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with MET Delta ex14 mutated advanced non-small cell lung cancer (NSCLC). Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Wolf, J., Seto, T., Han, J. Y., Reguart, N., Garon, E. B., Groen, H. J., Tan, D. S. W., Hida, T., de Jonge, M., Orlov, S., V, Smit, E. F., Souquet, P., Vansteenkiste, J., Le Mouhaer, S., Robeva, A., Waldron-Lynch, M., Balbin, A., Fairchild, L., Giovannini, M. and Heist, R. S. (2020). Capmatinib (INC280) in patients (pts) with METex14-mutated advances NSCLC: an update from phase 2 GEOMETRY mono-1 study. Pneumologie, 74. S. S134 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790